Features | Partner Sites | Information | LinkXpress
Sign In
Schiller
Ampronix
ElsMed

New Ultrasound Applications Detects Early Response to Pancreatic Cancer Therapy

By Medimaging International staff writers
Posted on 06 Mar 2013
Image: 3-D Ultrasound Molecular Imaging (USMI) images of nonresponder and responder pancreatic xenografts before (day 0) and after (day 2) treatment. The grayscale image shows a volume of the tumor and surrounding tissue. The green region is the molecular signal (Photo courtesy of the University of North Carolina).
Image: 3-D Ultrasound Molecular Imaging (USMI) images of nonresponder and responder pancreatic xenografts before (day 0) and after (day 2) treatment. The grayscale image shows a volume of the tumor and surrounding tissue. The green region is the molecular signal (Photo courtesy of the University of North Carolina).
In a recent study, investigators utilized dynamic contrast enhanced-perfusion imaging (DCE-PI) and ultrasonic molecular imaging (USMI) to gauge response to therapy for pancreatic cancer.

The research was published in the January 2013 issue journal Technology in Cancer Research and Treatment. Paul Dayton, PhD, University of North Carolina (UNC) Lineberger Comprehensive Cancer Center (Chapel Hill, USA), and senior author of the study, said, “What we found is that using two noninvasive technologies, we can detect response to therapy earlier than by relying on tumor volume changes. Having new noninvasive, inexpensive technologies available to measure response to therapy earlier during the course of treatment would be a significant advance in the ability to tailor a person’s treatment to improve outcomes.”

Dr. Dayton, a UNC associate professor of biomedical engineering, worked with Jen Jen Yeh, M.D, an associate professor of surgery and pharmacology, to assess the imaging technologies on human pancreatic cancer in a preclinical model. Both investigators are members of the Lineberger Comprehensive Cancer Center.

USMI has the ability to depict noninvasively the biologic processes at the cellular and molecular levels. It accomplishes this with the use of targeted contrast agents, which are markers that bind to specific proteins expressed on cancer cells within the body. These contrast agents enable a conventional ultrasound system to identify signals from cancer cells that would otherwise be undetectable.

Ultrasound DCE-PI is a technique used noninvasively to track the blood flow in the microcirculation. Because growing tumors require abnormally increased blood flow, alterations in blood vessel structure or density can provide data regarding tumor malignancy. The researchers employed a drug that suppresses a protein specific to tumors. They then used the imaging applications to gauge the response of two different tumors, one known to respond to the drug therapy, and a second known not to respond. The findings indicated that USMI was able to detect molecular signs of tumor response to therapy after only two days.

A change in blood flow in the tumor was seen to detect response after day 14 using DCE-PI. Over the same period, standard volume measurements were not able to detect therapeutic response, and prior studies suggested that volume measurements do not become indicative of response until approximately 28 days. Therefore, these modalities revealed a substantial improvement in the early identification of tumor response to therapy, using contrast enhanced ultrasound imaging.

The contrast agents for USMI currently in clinical trials in Europe for cancer imaging, however, they are not yet available in the United States.

Related Links:
University of North Carolina Lineberger Comprehensive Cancer Center



Channels

Radiography

view channel
Image: The Siemens Healthcare Somatom Force CT system (Photo courtesy of Siemens Healthcare).

New CT Scanning Technology Is Faster, Uses Less Radiation, and Easier on the Kidneys

Patients who must undergo computed tomography (CT) scanning now have a new option for screening that is extremely fast, uses less radiation, and is safer for the kidneys. With US Food and Administration... Read more

MRI

view channel
Image: In a preterm infant’s brain, an MRI scan can reveal abnormalities that were undetected by previous methods. The scans on the left show normal gray matter, while those on the right show abnormal gray matter (Photo courtesy of Washington University in St. Louis).

MRI Tracks Infant Brain Growth in First Months of Life

For the first time, researchers have used magnetic resonance imaging (MRI) of the newborn brain to calculate the volume of multiple brain regions and to map out regional growth trajectories during the... Read more

Nuclear medicine

view channel

PET Imaging Reveals Brain Benefits from Weight Loss After Bariatric Surgery

Imaging studies revealed that weight loss surgery has been found to suppress changes in brain metabolism associated with obesity and improve cognitive function involved in planning, strategizing, and organizing. Therefore, researchers have hypothesized that a specific surgical procedure could reduce risk of Alzheimer’s... Read more

General/Advanced Imaging

view channel

Diagnostic Imaging Tests Ordered by General Practitioners in Australia Nearly Double in 10 Years

A 45% increase in diagnostic imaging tests ordered by Australian general practitioners (GPs) is being fueled by increasing GP visits, an escalating number of problems managed at doctor visits, and a higher probability that GPs order imaging tests for these problems, according to a new study. Based on a long-term national... Read more

Imaging IT

view channel
Image: An X-ray using the ClearRead bone suppression software technology (Photo courtesy of Riverain Technologies).

Bone Suppression Software Used to Optimize Diagnostic Capability of X-Ray Systems

Clinicians are gathering important information from the most routine imaging exam, the chest X-ray, by using advanced software that enhances X-ray images captured by the equipment they already have or... Read more

Industry News

view channel

Acquisition Includes Radiation Simulation Software for Radiotherapy Applications

Varian Medical Systems, Inc. (Palo Alto, CA, USA) has acquired certain assets of Transpire, Inc. (Gig Harbor, WA, USA) including the Acuros dose calculation software, which has been incorporated into Varian’s BrachyVision and Eclipse treatment planning software systems. The acquisition closed at the end of July 2014.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.